Evidence map›Paper›PMID 36900073›Full record

ReviewDiagnostics (Basel, Switzerland)2023

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease.

Constantine E Kosmas, Shanna Rodriguez Polanco, Maria D Bousvarou, Evangelia J Papakonstantinou, Edilberto Peña Genao, Eliscer Guzman, Christina E Kostara

Full text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

197 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

137 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Constantine E KosmasDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA.
Shanna Rodriguez PolancoCardiology Clinic, Cardiology Unlimited, PC, New York, NY 10033, USA.ORCID 0009-0003-9849-2129
Maria D BousvarouSchool of Medicine, University of Crete, 710 03 Heraklion, Greece.
Evangelia J PapakonstantinouGeneral Directorate of Public Health and Social Welfare, Attica Region, 115 21 Athens, Greece.
Edilberto Peña GenaoCardiology Clinic, Cardiology Unlimited, PC, New York, NY 10033, USA.
Eliscer GuzmanDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA.
Christina E KostaraLaboratory of Clinical Chemistry, School of Health Sciences, Faculty of Medicine, University of Ioannina, 451 10 Ioannina, Greece.ORCID 0000-0001-7045-1323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis is an immunoinflammatory pathological procedure in which lipid plaques are formed in the vessel walls, partially or completely occluding the lumen, and is accountable for atherosclerotic cardiovascular disease (ASCVD). ACSVD consists of three components: coronary artery disease (CAD), peripheral vascular disease (PAD) and cerebrovascular disease (CCVD). A disturbed lipid metabolism and the subsequent dyslipidemia significantly contribute to the formation of plaques, with low-density lipoprotein cholesterol (LDL-C) being the main responsible factor. Nonetheless, even when LDL-C is well regulated, mainly with statin therapy, a residual risk for CVD still occurs, and it is attributable to the disturbances of other lipid components, namely triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). Increased plasma TG and decreased HDL-C levels have been associated with metabolic syndrome (MetS) and CVD, and their ratio, TG/HDL-C, has been proposed as a novel biomarker for predicting the risk of both clinical entities. Under these terms, this review will present and discuss the current scientific and clinical data linking the TG/HDL-C ratio with the presence of MetS and CVD, including CAD, PAD and CCVD, in an effort to prove the value of the TG/HDL-C ratio as a valuable predictor for each aspect of CVD.

Indexed as

cardiovascular diseasecerebrovascular diseasecoronary artery diseaseHDL-Cmetabolic syndromeperipheral artery diseaserisk markerTG/HDL-C ratiotriglycerides

Identifiers

PMID36900073
PMCPMC10001260

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read20
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.